Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1)
Patients with MIBC treated with AMVAC followed by a risk-adapted approach to local consolidation achieved a 2-year MFS rate of 73%. The primary end point was not met, but 17% of all enrolled patients and 48% of the AS group avoided cystectomy without metastatic disease.
Authors
- Philip H. Abbosh (ORCID: https://orcid.org/0000-0003-3611-9532)
- Elizabeth R. Plimack (ORCID: https://orcid.org/0000-0002-7618-0744)
- Daniel M. Geynisman (ORCID: https://orcid.org/0000-0002-1423-5295)
- David YT Chen (ORCID: https://orcid.org/0000-0003-4574-2027)
- Robert G. Uzzo (ORCID: https://orcid.org/0000-0003-2398-6530)
- Fern Anari (ORCID: https://orcid.org/0000-0001-9567-3205)
- Jean Hoffman‐Censits (ORCID: https://orcid.org/0000-0002-6970-6509)
- Eric A. Ross (ORCID: https://orcid.org/0000-0002-0890-2418)
- Eric M. Horwitz (ORCID: https://orcid.org/0000-0003-2187-317X)
- James Ryan Mark (ORCID: https://orcid.org/0000-0001-7675-3437)
- Matthew R. Zibelman (ORCID: https://orcid.org/0000-0003-1475-6477)
- M.A. Hallman (ORCID: https://orcid.org/0000-0002-2825-0656)
- Rosalia Viterbo
- Lambros Stamatakis (ORCID: https://orcid.org/0000-0002-2955-6411)
- Richard E. Greenberg (ORCID: https://orcid.org/0000-0002-8609-1307)
- Pooja Ghatalia (ORCID: https://orcid.org/0000-0001-6229-7581)
- Marc C. Smaldone (ORCID: https://orcid.org/0000-0003-4160-0005)
- Alexander Kutikov (ORCID: https://orcid.org/0000-0003-1525-6247)
- Thomas M. Churilla
Institutions
- MedStar Washington Hospital Center (US)
- Fox Chase Cancer Center (US)
- Thomas Jefferson University Hospital (US)
- Washington Hospital (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-12-16
- DOI
- https://doi.org/10.1200/jco-24-01214
- Citations
- 33
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 18.90